A Phase 1b/2 Trial with Tasquinimod in Patients with Myelofibrosis (primary, Post-PV or PostET) Refractory to or Intolerant for JAK2 Inhibition: the TasqForce Trial
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Tasquinimod (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 27 Sep 2024 New trial record